Literature DB >> 26825037

Endothelin-1 in the tumor microenvironment correlates with melanoma invasion.

Luis Chiriboga1, Shane Meehan, Iman Osman, Michael Glick, Gelo de la Cruz, Brittny S Howell, George Friedman-Jiménez, Robert J Schneider, Sumayah Jamal.   

Abstract

Endothelin-1 (ET-1) is a vasoactive peptide that also plays a role in the tanning response of the skin. Animal and cell culture studies have also implicated ET-1 in melanoma progression, but no association studies have been performed to link ET-1 expression and melanoma in humans. Here, we present the first in-vivo study of ET-1 expression in pigmented lesions in humans: an ET-1 immunohistochemical screen of melanocytic nevi, melanoma in situ lesions, invasive melanomas, metastatic melanomas, and blue nevi was performed. Twenty-six percent of melanocytic nevi and 44% of melanoma in situ lesions demonstrate ET-1 expression in the perilesional microenvironment, whereas expression in nevus or melanoma cells was rare to absent. In striking contrast, 100% of moderately to highly pigmented invasive melanomas contained numerous ET-1-positive cells in the tumor microenvironment, with 79% containing ET-1-positive melanoma cells, confirmed by co-staining with melanoma tumor marker HMB45. Hypopigmented invasive melanomas had reduced ET-1 expression, suggesting a correlation between ET-1 expression and pigmented melanomas. ET-1-positive perilesional cells were CD68-positive, indicating macrophage origin. Sixty-two percent of highly pigmented metastatic melanomas demonstrated ET-1 expression in melanoma cells, in contrast to 28.2% of hypopigmented specimens. Eighty-nine percent of benign nevi, known as blue nevi, which have a dermal localization, were associated with numerous ET-1-positive macrophages in the perilesional microenvironment, but no ET-1 expression was detected in the melanocytes. We conclude that ET-1 expression in the microenvironment increases with advancing stages of melanocyte transformation, implicating a critical role for ET-1 in melanoma progression, and the importance of the tumor microenvironment in the melanoma phenotype.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26825037     DOI: 10.1097/CMR.0000000000000235

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  5 in total

Review 1.  New insights on the role of autophagy in the pathogenesis and treatment of melanoma.

Authors:  Marveh Rahmati; Shiva Ebrahim; Saadeh Hashemi; Masoumeh Motamedi; Mohammad Amin Moosavi
Journal:  Mol Biol Rep       Date:  2020-10-09       Impact factor: 2.316

2.  Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma.

Authors:  Alexander Schäfer; Benedicte Haenig; Julie Erupathil; Panja Strickner; Daniela Sabato; Richard W D Welford; Lhéanna Klaeylé; Elise Simon; Clemens Krepler; Patricia Brafford; Min Xiao; Meenhard Herlyn; Matthias Gstaiger; Francois Lehembre; Imke Renz
Journal:  Oncogene       Date:  2021-01-26       Impact factor: 9.867

3.  Endothelin-1 down-regulates matrix metalloproteinase 14 and 15 expression in human first trimester trophoblasts via endothelin receptor type B.

Authors:  Alejandro Majali-Martinez; Philipp Velicky; Jürgen Pollheimer; Martin Knöfler; Hong Wa Yung; Graham J Burton; Nassim Ghaffari Tabrizi-Wizsy; Uwe Lang; Ursula Hiden; Gernot Desoye; Martina Dieber-Rotheneder
Journal:  Hum Reprod       Date:  2016-11-17       Impact factor: 6.918

Review 4.  Cutaneous melanoma: From pathogenesis to therapy (Review).

Authors:  Giulia C Leonardi; Luca Falzone; Rossella Salemi; Antonino Zanghì; Demetrios A Spandidos; James A Mccubrey; Saverio Candido; Massimo Libra
Journal:  Int J Oncol       Date:  2018-02-27       Impact factor: 5.650

Review 5.  Stromal Cells Present in the Melanoma Niche Affect Tumor Invasiveness and Its Resistance to Therapy.

Authors:  Justyna Mazurkiewicz; Aleksandra Simiczyjew; Ewelina Dratkiewicz; Marcin Ziętek; Rafał Matkowski; Dorota Nowak
Journal:  Int J Mol Sci       Date:  2021-01-07       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.